# A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines

> **NCT07665996** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hangzhou Highlightll Pharmaceutical Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria (CSU)

## Interventions

- **DRUG:** TLL-018
- **DRUG:** TLL-018
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07665996
- **Lead sponsor:** Hangzhou Highlightll Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665996, "A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*